Moderna Stock Surge After Cruise Hantavirus Cases
Moderna stock surge sent biotech peers higher as MV Hondius hantavirus reports spurred premarket trading despite WHO and CDC assessments of low public risk.
KEY TAKEAWAYS
- Moderna shares rose 9.4% after reports of a hantavirus outbreak aboard the MV Hondius.
- WHO and CDC assessed public-health risk as low while U.S. authorities continued monitoring.
- Investors focused on Moderna's prior hantavirus vaccine research and a $176 million award in 2024.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
Moderna, Inc. (MRNA) shares surged in premarket trading on May 11, 2026, following reports of a hantavirus outbreak aboard the MV Hondius cruise ship that sickened passengers and triggered U.S. monitoring, even as the World Health Organization and the Centers for Disease Control and Prevention assessed the public-health risk as low.
Cruise Hantavirus Outbreak and Public Health Response
The World Health Organization confirmed on May 2, 2026, that a hantavirus outbreak on the MV Hondius caused three deaths and six to eight confirmed infections among about 150 passengers. Hantaviruses are rodent-borne viruses. The CDC classified its federal response as Level 3 and described the public risk as extremely low.
On May 11, 2026, U.S. health authorities reported that a passenger on a repatriation flight tested mildly positive for the Andes strain of hantavirus, while another passenger showed mild symptoms.
Investor Reaction and Moderna’s Vaccine Program
Moderna shares rose 9.4% in premarket trading as investors focused on the outbreak. Other biotech stocks also gained, including Traws Pharma, which is developing hantavirus vaccine candidates, along with Emergent BioSolutions, Inovio, and Novavax.
Moderna’s hantavirus vaccine program includes a Phase 1 study reported as well-tolerated, with no serious safety concerns and a strong antibody response. The effort involves collaboration with the U.S. Army Medical Research Institute and Korea University and received a $176 million government award in 2024.
Financially, Moderna’s revenue declined from $19.3 billion in 2022 to $6.9 billion in 2023 and $3.2 billion in 2024. The company has secured European approvals for its mCOMBRIAX and mNEXSPIKE vaccines, which it expects to drive growth in the $1.8 billion European respiratory vaccine market through 2027. Moderna also raised its cost of sales to $1.8 billion, including a $900 million litigation settlement.
No new Moderna press releases or regulatory filings have appeared in the past 72 hours.
Evercore ISI analysts said the commercial opportunity for a hantavirus vaccine is likely limited and recent share gains appear sentiment-driven, noting that Moderna’s mRNA platform agility is probably already reflected in the stock price.
